A Post-treatment Program to Identify and Manage Complications Related to Oncology or Hematology Treatments in Cancer Survivors.
A Post-treatment Program to Identify and Manage Complications Related to Oncology or Hematology Treatments in Cancer Survivors.
INTRODUCTION: Approximately 44% of cancer survivors experience a deteriorated quality of life
 5 years after diagnosis due to late onset of complications related to cancer treatments. The
 objective of the study is to evaluate the incidence rates of treatment-related complications,
 identify sub-clinical abnormalities and risk factors in patients participating in the PASCA
 post-treatment program.

 METHOD: PASCA is a single-center, interventional cohort study of adult patients who received
 at least chemotherapy and with a complete remission to a testicular germ cell tumor, primary
 non-metastatic invasive breast carcinoma, high-grade soft tissue sarcoma, osteosarcoma,
 Ewing's sarcoma, acute myeloid leukemia, Hodgkin's or aggressive non-Hodgkin's lymphoma. Four
 assessment visits will be scheduled at 1 month (T1), 6 months (T2), 24 months (T3) and 60
 months (T4) after completion of treatment. During these visits, 22 complications will be
 screened and follow-up care will be systematically offered to the health professional
 concerned by the complication in case of a positive result. The screening will contain the
 following elements: screening self-questionnaires, quality of life questionnaire, 12
 biological parameters, a urinalysis evaluating hematuria, proteinuria, and leukocyturia, a
 spirometry, an electrocardiogram, 5 tests evaluating physical condition, vital signs and the
 perimetric measurement between both arms.

 DISCUSSION: This systematic screening could highlight a number of complications occurring
 after cancer treatments. Sub-clinical abnormalities and new risk factors could also be
 identified. This new organization of care could improve the quality of life of adult cancer
 survivors.
Inclusion Criteria:

 1. Age ≥ 18 years old and ≤ 65 years old.

 2. Follow-up at the Léon Bérard center

 3. Treated by chemotherapy for one of the following pathologies, and confirmed by the
 reference diagnostic technique :

 -  acute myeloid leukemia;

 -  Hodgkin's lymphoma;

 -  aggressive non-Hodgkin's lymphoma;

 -  primary non-metastatic invasive breast carcinoma;

 -  testicular germ cell tumor treated with at least 3 courses of BEP (bleomycin,
 etoposide, cisplatin), 4 courses of EP (etoposide, cisplatin) or 4 courses of VIP
 (etoposide, ifosfamide, cisplatin) received;

 -  high-grade soft tissue sarcoma, osteosarcoma or Ewing's sarcoma.

 4. As a complete response at the end of treatment consultation. If end-of-treatment
 evaluation is not available at the time of inclusion: as an assumed complete response
 in the opinion of the investigator based on the previous assessment of response.

 5. Whose capacity to practice an adapted physical activity will have been certified by a
 medical certificate issued by the investigating physician, the general practitioner or
 the referring physician.

 6. Able to understand, read and write French.

 7. Available and willing to participate in the project throughout the duration of the
 study.

 8. Living in the Auvergne-Rhône-Alpes region or in the department of Saône-et-Loire

 9. Affiliated with a health insurance plan.

 10. Having declared an attending physician.

 11. Having signed and dated the informed consent.

 Exclusion Criteria:

 1. With a history of malignancy other than basal cell skin cancer.

 2. Cannot be followed for medical, social, family, geographical or psychological reasons
 for the duration of the study.

 3. Participating in other studies that could impact on the evaluation of the judgement
 criteria.

 4. Deprived of liberty by judicial or administrative decision.